[fcb5af]: / literature / by_gene / SETD2.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 34977845 10.1016/j.xjidi.2021.100068 2022 Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. SETD2
2 35030632 10.1182/bloodadvances.2021006410 2022 Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. SETD2
3 35443279 10.1158/2159-8290.CD-21-1514 2022 SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. SETD2
4 35459873 10.1038/s41375-022-01571-8 2022 Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. SETD2
5 35522148 10.3324/haematol.2021.280005 2022 Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas. SETD2
6 35551151 10.1097/PAS.0000000000001914 2022 Targeted Next-generation Sequencing Reveals a Wide Morphologic and Immunophenotypic Spectrum of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. SETD2
7 35708139 10.3324/haematol.2022.281226 2022 Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. SETD2
8 35726023 10.1038/s41684-022-00998-x 2022 The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. SETD2
9 35895386 10.1111/bjd.21791 2022 Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. SETD2
10 35979577 10.3960/jslrt.22005 2022 Surface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma. SETD2
11 34406703 10.1002/ajh.26324 2021 The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study. SETD2
12 34576156 10.3390/ijms22189992 2021 Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy. SETD2
13 34895266 10.1186/s13000-021-01173-5 2021 Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases. SETD2
14 31028364 10.1038/s41379-019-0279-8 2020 Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. SETD2
15 31599770 10.1097/CCO.0000000000000590 2020 Novel molecular targets for the treatment of lung cancer. SETD2
16 31914529 10.3760/cma.j.issn.0529-5807.2020.01.004 2020 [Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases]. SETD2
17 32271188 10.1097/PAS.0000000000001470 2020 Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group. SETD2
18 32349779 10.1186/s13073-020-00739-0 2020 CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. SETD2
19 32469082 10.1002/cncr.32866 2020 Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. SETD2
20 32695399 10.1186/s40364-020-00205-4 2020 Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. SETD2
21 32853382 10.1182/bloodadvances.2019000938 2020 The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. SETD2
22 33260897 10.3390/cancers12123539 2020 Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows <i>SETD2</i> Alterations. SETD2
23 30307363 10.1080/15384047.2018.1523857 2019 Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). SETD2
24 31221981 10.1038/s12276-019-0230-6 2019 The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. SETD2
25 31344256 10.1111/bjh.16117 2019 The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. SETD2
26 31411343 10.1002/path.5333 2019 Genomic characterisation of breast fibroepithelial lesions in an international cohort. SETD2
27 28910456 10.1001/jamaoncol.2017.2918 2018 Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. SETD2
28 29305415 10.3324/haematol.2017.182444 2018 Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. SETD2
29 29337025 10.1016/j.humpath.2018.01.005 2018 Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. SETD2
30 29694893 10.1016/j.celrep.2018.03.124 2018 SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. SETD2
31 28122867 10.1158/2159-8290.CD-16-0330 2017 The Genetic Basis of Hepatosplenic T-cell Lymphoma. SETD2
32 28373165 10.1158/2159-8290.CD-17-0160 2017 It Takes a Village to Unmask HSTL. SETD2
33 28424246 10.1084/jem.20160894 2017 Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. SETD2
34 28612716 10.1051/medsci/20173305004 2017 [Molecular oncogenesis of lymphomas: role of the SETD2 gene in intestinal T-cell lymphomas]. SETD2
35 26527318 10.18632/oncotarget.6259 2016 Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. SETD2
36 26829311 10.1016/j.jtho.2016.01.010 2016 KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. SETD2
37 26839360 10.1136/thoraxjnl-2015-207950 2016 A patient with complex multiple genomic ALK alterations. SETD2
38 27181063 10.1016/j.exphem.2016.04.011 2016 Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. SETD2
39 27218135 10.1080/1062936X.2016.1186112 2016 Investigation of the inhibitors of histone-lysine N-methyltransferase SETD2 for acute lymphoblastic leukaemia from traditional Chinese medicine. SETD2
40 27505670 10.1016/j.ccell.2016.07.006 2016 EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. SETD2
41 27600764 10.1038/ncomms12602 2016 Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. SETD2
42 25444907 10.1016/j.canlet.2014.11.024 2015 Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. SETD2
43 24662245 10.1038/ncomms4469 2014 Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. SETD2
44 24710217 10.1038/ncomms4630 2014 The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. SETD2
45 23065515 10.3324/haematol.2012.066977 2013 The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis. SETD2
46 22237106 10.1038/nature10725 2012 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. SETD2